ABT · 8-K · 20261021PR066601

Operating Income and Margins

ABBOTT LABORATORIES · 2026-10-21 · Importance 58 · Surprise 56 · From source text

Third-quarter 2026 operating earnings fell 34.0% year over year to $1.358 billion despite 14.5% sales growth. Reported gross margin increased to $6.544 billion from $5.874 billion, but included $841 million of intangible amortization and $904 million of specified items. Reported operating costs and expenses increased 25.2% to $11.655 billion, including $841 million of amortization and $670 million of legal settlements within specified items. Adjusted net earnings increased 8.7% to $2.477 billion and adjusted diluted EPS increased 9.2% to $1.42, compared with $1.30 in the prior-year quarter.

Key facts

• Third-quarter operating earnings (Operating Earnings) 3Q26: $1,358 million, down 34.0% vs 3Q25 source
• 3Q26 net earnings: $920 million, down 44.1% vs $1,644 million in 3Q25 source
• Nine months operating earnings 9M26: $4,396 million, down 24.2% vs $5,802 million in 9M25 source
• Nine months net earnings 9M26: $2,925 million, down 38.4% vs $4,748 million in 9M25 source
• Net earnings excluding specified items for 3Q26: $2,477 million vs $2,278 million in 3Q25 source
• Nine months net earnings excluding specified items 9M26: $6,789 million vs $6,410 million in 9M25 source
• 9M26 diluted earnings per share: $1.67 vs $2.70 in 9M25 source
• 3Q26 diluted earnings per share excluding specified items: $1.42 vs $1.30 in 3Q25 source

Impact estimates